Yahoo Finance Multiple Reasons For the Outperformance of Halozyme Therapeutics (HALO)
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” fourth-quarter 2022 investor letter, a copy of which can be downloaded here. In the fourth quarter, the fund delivered a 10.36% net return compared to an 8.42% return for the Russell 2000 Value Index and a 9.21% return for the Russell 2500 Value Index. Health Care was the significant contributor to the fund’s performance in the quarter, while Materials detracted from the performance. In addition, please check the fund’s top five holdings to know its best picks in 2022.
Bernzott Capital Advisors highlighted stocks like Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the Q4 2022 investor letter. Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharma technology company. On January 20, 2023, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $51.46 per share. One-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was -10.49%, and its shares gained 48.30% of their value over the last 52 weeks. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a market capitalization of $6.958 billion.
Bernzott Capital Advisors made the following comment about Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its Q4 2022 investor letter:
“Halozyme Therapeutics, Inc. (NASDAQ:HALO): The company continued to post impressive royalty growth led by the subcutaneous forms of Janssen’s DARZALEX. Its May acquisition of Antares Pharmaceuticals has been integrated smoothly and product development with its auto-injector technologies is showing promise.”
Copyright: dolgachov / 123RF Stock Photo
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the third quarter which was 21 in the previous quarter.
We discussed Halozyme Therapeutics, Inc. (NASDAQ:HALO) in another article and shared Artisan Partners’ views on the company. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
Disclosure: None. This article is originally published at Insider Monkey.
